The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Top Cited Papers
- 4 January 2013
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 34 (4), 174-181
- https://doi.org/10.1016/j.it.2012.11.005
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in PsoriasisAmerican Journal of Human Genetics, 2012
- PSORS2 Is Due to Mutations in CARD14American Journal of Human Genetics, 2012
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin InflammationImmunity, 2011
- Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular PsoriasisAmerican Journal of Human Genetics, 2011
- Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography –Computed Tomography (FDG-PET/CT)Archives of Dermatology, 2011
- Psoriasis genetics: breaking the barrierTrends in Genetics, 2010
- Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasisJournal of Allergy and Clinical Immunology, 2010
- Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin DiseasesJournal of Clinical Immunology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008